Literature DB >> 9882027

Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study.

F K Chan1, J J Sung, R Suen, Y T Lee, J C Wu, W K Leung, H L Chan, A C Lai, J Y Lau, E K Ng, S C Chung.   

Abstract

BACKGROUND: Despite the widely accepted view that Helicobacter pylori is the most important cause of peptic ulcer disease, recent studies have suggested that the microbe protects against nonsteroidal anti-inflammatory drug (NSAID)-associated gastroduodenal lesions and promotes ulcer healing. We investigated the effects of H. pylori eradication on the healing of NSAID-associated bleeding peptic ulcers.
METHODS: Chronic NSAID users presenting with peptic ulcer haemorrhage underwent endoscopy to secure haemostasis and to document H. pylori infection by rapid urease test and culture. They were prospectively randomized to receive either omeprazole (20 mg once daily) for 8 weeks or a 1-week course of triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily) for 8 weeks. Endoscopy was repeated after 8 weeks. Final H. pylori status was determined by a 13C-urea breath test that was performed at least 4 weeks after discontinuation of omeprazole.
RESULTS: 195 H. pylori-infected NSAID users, complicated by bleeding ulcers, were randomized to receive omeprazole alone (102) or triple therapy plus omeprazole (93). 174 patients returned for second endoscopy at 8 weeks (91 in the omeprazole group, 83 in the triple therapy group). Urea breath test was negative in 14% in the omeprazole group vs. 92% in the triple therapy group (P < 0.001). Complete ulcer healing was achieved in 88 (97%) patients in the omeprazole group and 77 (93%) in the triple therapy group (P=0. 31). On intention-to-treat analysis, ulcers were healed in 86% of the omeprazole group and 83% of the triple therapy group (P=0.50). There was no significant difference in the healing rates of gastric or duodenal ulcers between the two groups.
CONCLUSION: Eradication of H. pylori did not impair the healing of NSAID-associated bleeding peptic ulcers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9882027     DOI: 10.1046/j.1365-2036.1998.00434.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

Review 1.  Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.

Authors:  R I Russell
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

2.  Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users.

Authors:  C Sostres; P Carrera-Lasfuentes; R Benito; P Roncales; M Arruebo; M T Arroyo; L Bujanda; L A García-Rodríguez; A Lanas
Journal:  Am J Gastroenterol       Date:  2015-04-21       Impact factor: 10.864

Review 3.  Helicobacter pylori infection.

Authors:  Grigorios I Leontiadis; Paul Moayyedi; Alexander Charles Ford
Journal:  BMJ Clin Evid       Date:  2009-10-01

Review 4.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies.

Authors:  A Pilotto
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.

Authors:  Mangesh A Thorat; Jack Cuzick
Journal:  Eur J Epidemiol       Date:  2014-11-25       Impact factor: 8.082

7.  NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite.

Authors:  Akiko Shiotani; Yoshio Yamaoka; Hala M T El-Zimaity; M Ali Saeed; Waqar A Qureshi; David Y Graham
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

8.  Helicobacter pylori and NSAID-induced gastric ulcer in a Japanese population.

Authors:  Kazunari Murakami; Tadayoshi Okimoto; Masaaki Kodama; Jin Tanahashi; Shigeaki Yasaka; Kunimitsu Inoue; Masahiro Uchida; Juro Anan; Kazuhiro Mizukami; Takashi Abe; Masahide Watada; Toshio Fujioka
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

9.  Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study.

Authors:  Aleksandra Sokic-Milutinovic; Miodrag Krstic; Brigita Rozer-Smolovic; Tamara Alempijevic
Journal:  Dig Dis Sci       Date:  2010-01-22       Impact factor: 3.199

10.  Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?

Authors:  Yuhong Yuan; Richard H Hunt
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.